Table 2.

Characteristics and Associations With Joint Infections Among 8026 Males With Haemophilia in the United States, 1999–2005

Characteristic	Controls (n = 7996)		Cases (n = 30)
	n	%	n	%	p value
Age
2–19	4428	55.4	6	20.0	<0.001
20–29	1269	15.9	1	3.3
30–39	816	10.2	7	23.3
≥40	1483	18.5	16	53.3
Race/ethnicity
White	5568	69.6	12	40.0	0.001
Black	999	12.5	10	33.3
Hispanic	971	12.1	5	16.7
Other	465	5.8	3	10.0
BMI
Underweight (<18.5)	1964	24.9	6	20.0	NS
Normal (18.5–24)	3069	38.9	8	26.7
Overweight (25–29)	1698	21.5	11	36.7
Obese (≥30+)	1164	14.7	5	16.7
Insurance type *
Commercial	1198	15.1	4	13.8	0.05
HMO/PPO	2757	34.6	5	17.2
Medicare/Medicaid	2295	28.8	8	27.6
Other/None	1707	21.5	12	41.4
Haemophilia Type
A	6359	79.5	27	90.0	NS
B	1637	20.5	3	10.0
Severity
Mild	1662	20.8	1	3.3	0.02
Moderate	1794	22.4	5	16.7
Severe	4540	56.8	24	80.0
Treatment Type
Episodic	5487	68.6	21	70.0	NS
Prophylaxis	2509	31.4	9	30.0
Home Infusion
Yes	6165	77.1	29	96.7	0.01
No	1831	22.9	1	3.3
CVAD
Yes	942	11.8	2	6.7	NS
No	7054	88.2	28	93.3
CVAD infection
Yes	99	1.2	0	0	NS
No	7897	98.8	30	100.0
Number of joint bleeds
0 bleeds	3427	42.9	3	10.0	0.003
1–2 bleeds	1557	19.5	8	26.7
3–6 bleeds	1401	17.5	10	33.3
7+ bleeds	1610	20.1	9	30.0
At least 1 target joint
Yes	1788	22.4	18	60.0	<0.001
No	6208	77.6	12	40.0
Invasive procedure
Yes	424	5.3	8	26.7	<0.001
No	7572	94.7	22	73.3
HIV status
Positive	1140	14.3	12	40.0	<0.001
Negative	6856	85.7	18	60.0
HCV status
Positive	3267	40.9	21	70.0	0.001
Negative	4729	59.1	9	30.0
Inhibitor
Yes	462	5.8	6	20.0	0.001
No	7534	94.2	24	80.0

Columns may not sum to n or to 100% because of missing data

^*Patients may have more than one insurance type.